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Abstract
Background Tapentadol prolonged release (PR; 100–250
mg twice daily) has been efficacious and well tolerated for
managing moderate-to-severe, chronic osteoarthritis hip or
knee pain in phase 3 studies with washoutof previous analgesic
treatment.
Objective The objective of this study was to evaluate the
effectiveness and tolerability of tapentadol PR (50–250 mg
twice daily) after direct rotation from World Health
Organization (WHO) step III opioids in patients with
severe osteoarthritis knee pain who previously responded
to WHO step III therapy but showed poor tolerability.
Methods This open-label, phase 3b study (NCT00982280)
was conducted from October 2009 through June 2010
(prematurely terminated due to slow recruitment and study
drug shortages) in clinical care settings in Europe and
Australia. The study population included patients with
severe, chronic osteoarthritis knee pain who had taken
WHO step III opioids daily for C2 weeks before screening,
responded to therapy (average pain intensity [11-point
numerical rating scale-3 (NRS-3)] B5 at screening), and
reported opioid-related adverse effects as their reason for
changing analgesics. Patients switched directly from WHO
step III therapy to tapentadol. Patients received oral ta-
pentadol PR (50–250 mg twice daily) during 5-week
titration and 7-week maintenance periods. Oral tapentadol
immediate release (IR) was permitted (Btwice/day, C4 h
apart) for acute pain episodes due to index pain or with-
drawal symptoms following discontinuation of previous
opioids (combined dose of tapentadol [PR and IR]
B500 mg/day). This study was planned to evaluate con-
version to tapentadol PR, based on responder rate 1 (per-
centage of patients with same/less pain [NRS-3] versus
Week -1) at Week 6 (primary endpoint), adverse events
(AEs), and discontinuation rates. Equianalgesic ratios were
calculated for tapentadol prior to WHO step III opioids (PR
and PR plus IR formulations).
Results Of 82 patients enrolled, 63 received study med-
ication. In the per-protocol population, responder rate 1 at
Week 6 (last observation carried forward) was 94.3 % (50/
53; P \ 0.0001 vs. the null hypothesis rate [\60 %]).
Mean (standard deviation) pain intensity scores were 4.7
(0.66) at baseline, 2.5 (1.46) at Week 6, and 1.8 (1.41) at
Week 12 in the main analysis population (change from
baseline at Weeks 6 and 12, P \ 0.0001). Tapentadol to
transdermal buprenorphine equianalgesic ratios (PR
[n = 48], 262.9:1; PR plus IR [n = 48], 281.1:1) and ta-
pentadol to oral oxycodone equianalgesic ratios (PR
[n = 4], 4.3:1; PR plus IR [n = 6], 4.6:1) were calculated
for the main analysis population. In the safety population,
prevalence of AEs reported as associated with prior opioids
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at Week -1 (reasons for rotation) and related to tapentadol
treatment at Week 12 decreased over time; the most
common were nausea (46.0 vs. 24.1 %) and constipation
(31.7 vs. 7.4 %). Overall, 14.3 % of patients discontinued
the study early; reasons included AEs (9.5 %), lack of
efficacy (3.2 %), and withdrawal of consent (1.6 %).
Conclusions Significant improvements in effectiveness
were observed for tapentadol PR (50–250 mg twice daily)
versus WHO step III opioids in patients with severe,
chronic osteoarthritis knee pain who previously responded
to WHO step III therapy. Equianalgesic ratios were cal-
culated for tapentadol to transdermal buprenorphine and
oral oxycodone and were in line with observations from
previous phase 3 studies.
1 Introduction
Opioids are used to manage osteoarthritis pain in patients
who have not responded to more conservative pharmaco-
logical options [1–3] and are effective for the relief of
moderate-to-severe, chronic osteoarthritis pain [4–6]. Evi-
dence suggests that disturbed descending pain inhibition
often plays a role in osteoarthritis pain [7–10]. The prev-
alence of chronic pain following joint replacement surgery
ranges from 27 to 44 % [11–13]; central sensitization
associated with disturbed descending pain inhibition is
thought to contribute to this pain [14]. Central sensitization
may lead to variations in patient response to opioid therapy
[7, 9]. Constant nociceptive pain resulting from cartilage
degradation [15] and disruption of descending inhibitory
pain pathways may also contribute to osteoarthritis pain [7,
16, 17]. The multi-mechanistic origin of osteoarthritis pain
may complicate pain control; analgesics with multiple
mechanisms of analgesic activity, including those that
target descending pain pathways (e.g., noradrenaline re-
uptake inhibition), may be more effective than those with a
single mechanism of action (e.g., opioids) [7, 16, 17].
Long-term opioid therapy offers only moderate benefits for
patients with osteoarthritis pain and is often associated with
poor tolerability that may lead patients to discontinue
opioid treatment or switch to a different opioid, resulting in
interruption of pain control [4, 18–21].
Tapentadol is a centrally acting analgesic with two
mechanisms of action, l-opioid receptor agonism and
noradrenaline reuptake inhibition [22, 23]. Previous phase
3 studies have shown that tapentadol prolonged release
(PR; 100–250 mg twice daily) is effective and well toler-
ated for managing moderate-to-severe, chronic pain, such
as osteoarthritis pain [24–26], low back pain [25–27], and
pain related to diabetic peripheral neuropathy [28, 29].
Most ([75 %) patients in those studies reported severe
pain at baseline [24–28]. A separate phase 3b study
demonstrated the effectiveness and tolerability of tapen-
tadol PR in patients with severe, chronic osteoarthritis knee
pain who had not responded adequately to World Health
Organization (WHO) step I or II analgesics or co-analge-
sics or who were not receiving regular analgesic treatment
[30]. The current multicenter, multinational, open-label
phase 3b study (NCT00982280) evaluated the effectiveness
and tolerability of tapentadol PR in patients with severe,
chronic osteoarthritis knee pain who had responded to
WHO step III opioid therapy but showed a lack of tolera-
bility; direct rotation of these patients from their previous
WHO step III treatment to tapentadol PR was studied and
equianalgesic ratios of tapentadol to prior WHO step III
opioids were evaluated.
2 Methods
This study was conducted in accordance with the ethical
principles of the Declaration of Helsinki, Good Clinical
Practice guidelines, and applicable local laws. Prior to
study enrollment, all patients signed an informed consent
document. The study protocol, patient information sheet,
and informed consent form were approved by independent
ethics committees.
2.1 Patient Population
This study included men and non-pregnant, non-lactating
women diagnosed with knee osteoarthritis based on the
following American College of Rheumatology criteria:
knee pain and radiographic osteophytes or knee pain,
C40 years of age, morning stiffness of \30 min duration,
and crepitus on motion. Eligible patients must have been
experiencing pain requiring a strong (WHO step III)
analgesic at the reference joint for C3 months. The target
population included patients who had been taking WHO
step III opioids for C2 weeks before screening and had
responded to that treatment (average pain intensity during
the last 3 days before screening B5 on an 11-point
numerical rating scale-3 [NRS-3; recalled 3-day average
pain intensity (11-point NRS); 0 = ‘‘no pain’’ to 10 = ‘‘pain
as bad as you can imagine’’]). Eligible patients had to
report opioid-related adverse effects as their reason for
changing analgesics, and subject satisfaction with treat-
ment ratings could not be better than ‘‘fair’’ (5-point verbal
rating scale; 0 = ‘‘poor’’ to 4 = ‘‘excellent’’).
Patients were excluded if they had a history of alcohol
or drug abuse; severe renal impairment; moderate or severe
hepatic impairment; active hepatitis B or C within 3
months of screening; reported HIV infection (HIV testing
was not performed); seizure disorder or epilepsy; mild or
moderate traumatic brain injury, stroke, transient ischemic
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attack, or brain neoplasm within the past year; or severe
traumatic brain injury within the past 15 years or residual
sequelae suggesting potential transient changes in
consciousness. Patients were also excluded if they had
concomitant autoimmune inflammatory conditions; osteo-
arthritis in a flare state; history and clinical signs of crystal-
induced, metabolic, infectious, or autoimmune disease at
the reference joint; any painful procedure required during
the study that could affect efficacy or safety assessments; or
the presence of painful conditions other than osteoarthritis
of the reference joint that could confound self-assessment of
pain. Patients with osteoarthritis at joints other than the
reference joint were not excluded from the study if the main
source of their pain and disability was the reference joint.
Use of monoamine oxidase inhibitors within 14 days of
screening or intra-articular injections of hyaluronic acid at
the reference joint within 3 months of screening was pro-
hibited. Patients were permitted to take selective serotonin
reuptake inhibitors if they had been taking stable doses for
C30 days prior to screening and if doses remained stable
throughout the study.
2.2 Study Design
This open-label, multicenter, phase 3b study included a
1-week observation period under the previous WHO step
III regimen (Week -1, starting with screening and ending
with baseline), a 5-week titration and stabilization period,
and a 7-week maintenance period. All WHO step III
analgesics and potential concomitant WHO step II anal-
gesics were discontinued at the end of the observation
period. The average total daily dose (TDD) of WHO step
III analgesics (including all formulations of all opioids
taken) used over the last 3 days before the baseline visit
were converted into a morphine equivalent dose (MED).
The starting dose of tapentadol PR (50, 100, or 150 mg
twice daily) was determined based on the MED range for
the patient’s previous WHO step III analgesic(s) (Table 1).
An interim visit occurred 3–4 days after the baseline
visit (i.e., 3–4 days after initiation of study treatment). A
first titration corresponding with the interim visit was
allowed; doses were then titrated on a weekly basis to the
dose providing an optimal balance of pain relief and tol-
erability within the therapeutic range of tapentadol PR
50–250 mg twice daily. Titration was continued until
patients achieved at least similar pain relief (i.e., the same
or less pain intensity [11-point NRS-3]) compared with the
previous WHO step III analgesic treatment.
Throughout the study, patients continued taking any
WHO step I analgesics, co-analgesics, or medications used
to control adverse effects related to the prior opioid regi-
men at the same stable dose, unless they were participating
in a tapering substudy as described below. Laxatives could
be discontinued if laxative-induced diarrhea occurred after
patients switched to tapentadol PR. Patients were permitted
to take tapentadol immediate release (IR) 50 mg (Btwice/
day, C4 h apart) as backup medication throughout the
study for acute pain episodes due to index pain or for
withdrawal symptoms that occurred during the first days of
the titration period following discontinuation of the previ-
ous opioid (combined TDD of tapentadol IR and PR,
B500 mg). During the maintenance period, patients con-
tinued on the dose of tapentadol PR determined during
titration. For Substudy A, one concomitant WHO step I
analgesic or co-analgesic was tapered from Week 9 to
Week 11 until the analgesic or co-analgesic was stopped or
the patient’s pain intensity score increased; co-analgesics
had priority for tapering. For Substudy B, concomitant
medications used to control adverse effects related to the
previous opioid analgesic were tapered and stopped during
Week 7.
2.3 Study Evaluations
Study evaluations were performed using one or more of the
following populations: safety (all patients who took C1
dose of study drug), main analysis (all patients who took
C1 dose of study drug and had C1 post-baseline pain
intensity assessment), and per-protocol (subset of the main
analysis population; all patients who received treatment up
to and including Week 6 and had no major protocol
deviations).
The primary endpoint was responder rate 1 (percentage
of patients with the same/less pain compared with Week
-1 [on previous WHO step III analgesic]) at Week 6 in the
per-protocol population, using the last observation carried
forward (LOCF) for imputing missing pain intensity
assessments. Responder rate 2 (percentage of patients with
the same/less pain and improvement of C1 category in
subject satisfaction with treatment compared with baseline)
at Week 6 (LOCF) was a secondary endpoint in the per-
protocol population. Responder rates 1 and 2 were also
evaluated at Weeks 6, 8, and 12 in the main analysis
population using observed-case analysis. Observed-case
Table 1 Tapentadol prolonged release starting doses based on mor-
phine equivalent doses
Average MED per daya Starting dose of
tapentadol PR per day
B100 mg/day 50 mg bid
101–160 mg/day 100 mg bid
[160 mg/day 150 mg bid
MED morphine equivalent dose, PR prolonged release, bid twice
daily
a Includes all formulations of all strong opioids taken
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analyses for responder rates and all other endpoints inclu-
ded results for all patients who received C1 dose of ta-
pentadol PR and had C1 post-baseline pain intensity
assessment. Additional analyses included pain intensity
ratings (NRS-3), subject satisfaction with treatment,
Patient Global Impression of Change (PGIC) [31, 32],
Clinician Global Impression of Change (CGIC) [33],
Western Ontario and McMaster Universities (WOMAC)
Osteoarthritis Index [34], EuroQol-5 Dimension (EQ-5D)
[35], Short Form-36 (SF-36) [36], Hospital Anxiety and
Depression Scale (HADS) [37], and a 4-item sleep ques-
tionnaire [38].
Safety and tolerability assessments included adverse
event (AE) reporting and laboratory and vital sign evalu-
ations. AEs were categorized as treatment-emergent AEs
(TEAEs; AEs that occurred after the first intake of study
drug or increased in intensity, frequency, or quality during
treatment with study drug), and non-TEAEs (NTEAEs;
AEs that occurred or were present prior to the first intake of
study drug, including ongoing medical history). AEs were
considered at least possibly related to study drug admin-
istration if there was evidence suggesting a causal rela-
tionship and unlikely or not related if there was no
evidence of a causal relationship. AEs were evaluated for
at least a possible association with any WHO step III
analgesics and co-analgesics. Incidence, intensity, duration,
and causality of all AEs were analyzed. The prevalence of
AEs reported as associated with treatment at Week -1 (on
WHO step III treatment) and related to treatment at Week
12 (on tapentadol PR treatment) were compared.
2.4 Statistical Analyses
A sample size of 178 patients was required to provide 80 %
power to perform all three of the following analyses in a
stepwise manner (given the rejection of the null hypothesis
at the first two steps): comparison of a responder rate 1 of
C60 % and the null hypothesis responder rate (\60 %;
non-inferiority margin, 14.3 %), comparison of a responder
rate 2 of C60 % and the null hypothesis responder rate
(\60 %; non-inferiority margin, 14.3 %), and rejection of
the null hypothesis that mean pain intensity score at Week
6 was not equivalent to that at Week -1 (i.e., the difference
in means was C0.673 away from 0) in favor of the alternate
hypothesis that responder rate 1 was C60 %.
A one-sample Chi-square test was used to analyze
responder rates 1 and 2 in the per-protocol population at
Week 6 (LOCF) and in the main analysis population at
Weeks 6, 8, and 12 (observed-case). A one-sample paired
t-test was used to analyze the changes from baseline to
Weeks 6, 8, and 12 in mean pain intensity, WOMAC
subscale and global scores, EQ-5D health status index and
patient-rated health state (100-mm visual analog scale
[VAS]) scores, HADS anxiety and depression subscale
scores, and SF-36 subscale and summary scores.
Equianalgesic ratios of tapentadol to previous WHO
step III analgesics were calculated. The mean TDD
(average TDD during the 3 days prior to the visit) of ta-
pentadol at which a pain intensity score (NRS-3) equiva-
lent to or less than the pain intensity score at baseline (on
previous WHO step III regimen) was reached was defined
as the equipotent dose. The corresponding mean TDD of
WHO step III analgesic was the average of the TDDs taken
during the 3 days before baseline. Equianalgesic ratios
were calculated for combined tapentadol PR and tapentadol
IR to combined WHO step III PR and IR opioid analgesics
and for tapentadol PR to WHO step III PR opioid
analgesics.
Analyses were performed using two separate datasets
(one that included results from Weeks 9–12 for patients
who participated in Substudy A and one that excluded
those results) because of the possibility that tapering of
WHO step I analgesics and co-analgesics during Weeks 9
through 12 might result in pain peaks that could influence
effectiveness, function, and quality-of-life analyses.
Results presented here are for the dataset that included
results from Weeks 9 through 12 for patients who partici-
pated in Substudy A in the main analysis population using
observed-case analysis (unless otherwise specified); results
of analyses for the dataset that excluded results from
Weeks 9 through 12 for patients who participated in Sub-
study A using observed-case analysis and LOCF are sum-
marized in the Electronic Supplementary Material.
3 Results
3.1 Patients
The numbers of patients in the safety (n = 63), main
analysis (n = 62), and per-protocol (n = 53) populations
were lower than initially planned because this study was
terminated prematurely due to slow recruitment and study
drug shortages. Baseline and demographic characteristics
for the safety population are summarized in Table 2. In the
safety population, the mean (standard deviation [SD])
duration of osteoarthritis knee pain was 6.45 (5.92) years.
Overall, 14.3 % (9/63) of patients in the safety population
discontinued the study early for reasons including AEs
(9.5 % [6/63]), lack of efficacy (3.2 % [2/63]), and with-
drawal of consent (1.6 % [1/63]).
During Week -1, 14.3 % (9/63) of patients were taking
co-analgesics, 52.4 % (33/63) were taking WHO step I
analgesics, 11.1 % (7/63) were taking WHO step II opioid
analgesics, and 100 % (63/63) were taking WHO step III
opioid analgesics (according to the inclusion criteria). The
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WHO step III analgesics taken during Week -1 were bu-
prenorphine (transdermal system; 77.8 % [49/63]), oxy-
codone (15.9 % [10/63]), hydromorphone (6.3 % [4/63]),
morphine (4.8 % [3/63]), and methadone (1.6 % [1/63]).
The mean release rate of transdermal buprenorphine (the
most commonly used WHO step III analgesic during Week
-1) was 21.46 lg/h, corresponding to an average
buprenorphine dose of about 0.52 mg/day. The MEDs of
the TDDs of WHO step III opioids that patients were
taking at baseline are summarized in Table 3.
Concomitant WHO step I analgesics were taken by
55.6 % (35/63) of patients and concomitant co-analgesics
were taken by 14.3 % (9/63) of patients. A total of 55.6 %
(35/63) of patients took concomitant medications to treat
adverse effects, including adverse effects related to their
previous opioid therapy.
3.2 Effectiveness, Function, and Quality-of-Life
In the per-protocol population, responder rate 1 (percentage
of patients with the same/less pain compared with Week
-1) at Week 6 (LOCF) was 94.3 % (50/53), which was
significantly different from the null hypothesis responder
rate 1 of \60 % (P \ 0.0001). Responder rate 2 (per-
centage of patients with the same/less pain and an
improvement of C1 category in subject satisfaction with
treatment) at Week 6 (LOCF) was 92.5 % (49/53) in the
per-protocol population and was significantly different
from the null hypothesis responder rate 2 of \60 %
(P \ 0.0001). In the main analysis population (n = 62),
responder rates 1 and 2 increased from the interim visit to
Week 4 (observed-case analysis) and remained at approx-
imately 90 % or above until Visit 12 (Fig. 1).
Significant reductions from baseline were observed in
the mean pain intensity score at Weeks 6, 8, and 12 in the
main analysis population (P \ 0.0001 for the change from
baseline for all comparisons; Fig. 2). Mean (SD) pain
intensity scores were 4.6 (0.63) at screening, 4.7 (0.66) at
baseline, 2.5 (1.46) at Week 6, and 1.8 (1.41) at Week 12.
Mean (SD) changes in pain intensity from baseline to
Weeks 6 and 12 were -2.2 (1.55) and -2.9 (1.40),
respectively (P \ 0.0001 for both comparisons). The per-
centage of patients who rated their satisfaction with treat-
ment as ‘‘excellent,’’ ‘‘very good,’’ or ‘‘good’’ increased
from 1.6 % (1/62) at baseline to 92.7 % (51/55) at Week 6
and 94.4 % (51/54) at Week 12 (Fig. 3). Satisfaction with
treatment was rated as ‘‘poor’’ by 24.2 % (15/62) of
patients at baseline and by no patients at Weeks 6 or 12. On
the PGIC and CGIC, respectively, ratings of the patient’s
overall condition as ‘‘very much improved,’’ ‘‘much
improved,’’ or ‘‘minimally improved’’ were reported by
94.5 % (52/55) of patients and 94.5 % (52/55) of investi-
gators at Week 6 and by 92.6 % (50/54) of patients and
94.4 % (51/54) of investigators at Week 12 (Fig. 4).



































Responder rate 2Responder rate 1
Fig. 1 Responder rates 1 and 2 over time (main analysis population;
observed-case analysis)a. WHO World Health Organization
aResponder rate 1 was the percentage of patients with the same or less
pain compared with Week -1 (on previous WHO step III analgesic);
responder rate 2 was the percentage of patients with the same or less
pain compared with Week -1 and an improvement of C1 category in
subject satisfaction with treatment compared with baseline
bP \ 0.0001 for testing the hypothesis that the response is 50 %
cThe interim visit occurred 3–4 days after the baseline visit
Table 2 Baseline and demographic characteristics (safety
population)
Characteristic Total (n = 63)






Mean (SD) body mass index, kg/m2 31.3 (5.61)
SD standard deviation
Table 3 Morphine equivalent doses of previous World Health
Organization step III opioids at baseline
Average MEDa Total, n (%) [n = 62]b
B100 mg/day 54 (87.1)
101–160 mg/day 4 (6.5)
[160 mg/day 4 (6.5)
MED morphine equivalent dose
a Includes all formulations of all opioids taken
b The MED cohort was unknown for one patient in the safety
population
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Mean WOMAC, EQ-5D, SF-36, HADS, and sleep
questionnaire scores at baseline, Week 6, and Week 12 are
reported in Electronic Supplementary Material Tables
S5–S9. Significant improvements from baseline in mean
WOMAC global score and pain, stiffness, and physical
function subscale scores were observed at Weeks 6, 8, and
12 (P \ 0.0001 for all comparisons; Fig. 5). On the EQ-
5D, mean health status index score improved significantly
from baseline to Week 6 (mean [SD] change from baseline,


































1 2 3 4 5 6 7 8 9 10 11 12
n 62 626261 59 56 55 55 55 55 55 54 55 54 53
b
b b
Fig. 2 Mean pain intensity (NRS-3) over time (main analysis
population; observed-case analysis)a. The vertical dotted line indi-
cates start of tapentadol prolonged release. NRS-3 numerical rating
scale-3, W week, WHO World Health Organization
aStandard deviations: screening, 0.63; baseline, 0.66; interim, 1.03;
W1, 1.33; W2, 1.40; W3, 1.02; W4, 1.14; W5, 1.20; W6, 1.46; W7,
1.47; W8, 1.40; W9, 1.37; W10, 1.60; W11, 1.45; W12, 1.41
bPreplanned statistical analyses of change from baseline were
conducted at Weeks 6, 8, and 12; P \ 0.0001 for the change from
baseline at each timepoint
cOn WHO step III analgesics
dEnrollment to baseline (i.e., point of rotation to tapentadol prolonged
release)










































Fig. 3 Subject satisfaction with treatment at baseline, Week 6, and
Week 12 (main analysis population; observed-case analysis)





























































































Fig. 4 Ratings on the a PGIC and b CGIC at Weeks 6 and 12 (main
analysis population; observed-case analysis). PGIC Patient Global
Impression of Change, CGIC Clinician Global Impression of Change
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P \ 0.0001), and Week 12 (0.26 [0.313]; P \ 0.0001), as
did mean VAS score (Week 6, 29.6 [15.37]; Week 8, 33.0
[17.40]; Week 12, 35.5 [18.33]; P \ 0.0001 for all com-
parisons). Significant improvements from baseline were
observed in all individual mean SF-36 domain scores at
Weeks 6 and 12 (P B 0.0005 for all comparisons), except for
role-emotional (numerical improvements were observed
from baseline but they were not statistically significant;
Week 6, P = 0.5515; Week 12, P = 0.4976; Fig. 6). The
mean SF-36 physical component summary score also
improved significantly from baseline to Week 6 (mean [SD]
change from baseline, 11.9 [10.52]; P \ 0.0001) and Week
12 (15.6 [14.44]; P \ 0.0001). No significant changes from
baseline were observed in mean SF-36 mental component
summary score at Week 6 (mean [SD] change from baseline,
0.5 [7.09]; P = 0.6070) or at Week 12 (0.1 [8.28];
P = 0.9657; Electronic Supplementary Material Table S7).
Significant decreases from baseline were observed in
mean HADS anxiety and depression scores at Weeks 6, 8,
and 12 (P \ 0.05 for all comparisons). Mean (SD) HADS
anxiety and depression subscale scores at baseline were 5.2
(4.26) and 5.1 (4.64), respectively; these scores were both
below the range corresponding to clinically manifested
anxiety and depression (scores C8 are considered to indi-
cate the likely presence of anxiety or depression [39]). For
the HADS anxiety and depression subscale scores,
respectively, mean (SD) changes from baseline were -1.1
(2.86) and -0.9 (2.41) at Week 6 and -1.4 (2.76) and -1.1
(3.00) at Week 12.
On the sleep questionnaire, the mean (SD) number of
awakenings per night decreased significantly from baseline
(2.3 [1.54] awakenings) to Week 6 (1.1 [1.12] awakenings)
and Week 12 (1.1 [1.06] awakenings; P \ 0.0001 for the
change from baseline to Weeks 6 and 12). The mean (SD)
number of hours slept per night increased significantly
from baseline (6.6 [1.38] h) to Week 6 (7.0 [1.09] h) and
Week 12 (7.0 [1.19] h; P \ 0.05 for the change from
baseline to Weeks 6 and 12). At baseline, Week 6, and
Week 12, respectively, overall sleep quality ratings of
‘‘excellent’’ or ‘‘good’’ were reported by 37.1 % (23/62),
63.6 % (35/55), and 68.5 % (37/54) of patients.
Results for effectiveness, function, and quality-of-life
measures were comparable for the dataset that included
results from Weeks 9 through 12 for patients who partici-
pated in Substudy A and the dataset that excluded those
results (Electronic Supplementary Material Tables S1–S9).
When the LOCF was used for imputing missing data,
improvements were generally consistent with those shown
when no imputation method was used (observed-case anal-
ysis; Electronic Supplementary Material Tables S1–S9).
3.3 Treatment Exposure and Equianalgesia
In the overall population, 83.9 % (52/62) of patients
required no adjustment of their tapentadol PR starting dose
up to Week 6 and 3.2 % (2/62) of patients required one
adjustment to achieve the same or less pain intensity com-
pared with baseline (LOCF; responders, based on responder
rate 1 definition). Five (8.1 %) patients were non-respond-
ers (based on responder rate 1 definition) and did not adjust
their dose of tapentadol PR up to Week 6, one (1.6 %)
patient was a non-responder and had one dose adjustment,
and two (3.2 %) patients were non-responders and had three
dose adjustments. At Week 6, the mean (SD) TDD of ta-
pentadol PR was 232.7 (145.37) mg, and the mean (SD)
TDD of tapentadol IR was 7.0 (17.48) mg. The percentages
of patients taking tapentadol PR and tapentadol IR in each
dose range are summarized in Table 4. The most commonly
used dose of tapentadol PR at Week 6 was 50 mg twice
daily (taken by 41.8 % [23/55] of patients). Most patients
(78.2 % [43/55]) did not take tapentadol IR once they
achieved stable dosing with tapentadol PR at Week 6. The
equianalgesic ratios for tapentadol to transdermal bu-
prenorphine and oral oxycodone are shown in Table 5.
Equianalgesic ratios for tapentadol to other prior WHO step
III opioids are not presented due to low patient numbers.
3.4 Safety and Tolerability
Overall, 98.4 % (62/63) of patients in the safety population
reported NTEAEs (under the previous analgesic regimen;
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Stiffness subscale score (possible score, 0-8)d
Pain subscale score (possible score, 0-20)c
Physical function subscale score (possible score, 0-68)b
Global score (possible score, 0-96)a
Fig. 5 Mean WOMAC subscale and global scores over time (main
analysis population; observed-case analysis). WOMAC Western
Ontario and McMaster Universities, SDs standard deviations, W week
aSDs: baseline, 13.19; W6, 16.72; W8, 19.57; W12, 19.00
bSDs: baseline, 9.88; W6, 12.40; W8, 14.26; W12, 14.04
cSDs: baseline, 2.48; W6, 3.45; W8, 3.94; W12, 3.59
dSDs: baseline, 1.76; W6, 1.52; W8, 1.80; W12, 1.78
eP \ 0.0001 for the change from baseline
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Of the 255 NTEAEs reported, 158 (62.0 %) were consid-
ered to be non-associated with previous analgesic or co-
analgesic treatment and 97 (38.0 %) were considered to be
associated with previous analgesic or co-analgesic treat-
ment. According to the study inclusion criteria, all eligible
subjects were required to report opioid-related adverse
effects as their reason for switching their analgesic
treatment.
The prevalence of the AEs reported as associated with
previous treatment during Week -1 and related to ta-
pentadol treatment at Week 12 (Fig. 7) generally decreased
during the study under treatment with tapentadol. Nausea,
constipation, dry mouth, fatigue, and dizziness were among
the most commonly reported AEs associated with previous
treatment at Week -1 and the most commonly reported
reasons for switching to tapentadol PR; the prevalence of





















































































































Fig. 6 Mean (SD) changes in
SF-36 domain scores from
baseline to a Week 6a and
b Week 12b (main analysis
population; observed-case
analysis)c,d. SD standard
deviation, SF-36 Short Form-36
aSD: physical functioning,
21.99; role-physical, 41.88;
bodily pain, 20.67; general
health, 13.25; vitality, 13.92;
social functioning, 27.39; role-




bodily pain, 29.28; general
health, 15.59; vitality, 15.75;
social functioning, 27.79; role-
emotional, 33.50; mental health,
12.12
cSee Electronic Supplementary
Material Table S7 for mean total
SF-36 scores at baseline, Week
6, and Week 12
dWeek 6, n = 55; Week 12,
n = 53
eP B 0.0005 for the change
from baseline
fn = 52
Table 4 Doses of tapentadol prolonged release and tapentadol
immediate release at Week 6 (main analysis population)
Dose Total, n (%) [n = 55]
Tapentadol PR
50 mg bid 23 (41.8)
100 mg bid 13 (23.6)
150 mg bid 3 (5.5)
200 mg bid 10 (18.2)
250 mg bid 6 (10.9)
Tapentadol IR
None 43 (78.2)
[0 to \50 mg 9 (16.4)
50 mg 2 (3.6)
100 mg 1 (1.8)
PR prolonged release, bid twice daily dosing, IR immediate
release
614 I. Steigerwald et al.
At least one TEAE was reported from Week 1 to Week
12 by 34.9 % (22/63) of patients. Of the 116 TEAEs
reported, 73 (62.9 %) were classified as at least possibly
related to study drug. The majority of TEAEs reported
were of mild or moderate intensity (85.3 % [99/116]). The
most commonly reported (incidence C5 %) TEAEs
(Fig. 8) included diarrhea, nausea, dizziness, constipation,
hyperhidrosis, drug withdrawal syndrome, and fatigue,
which are known adverse drug reactions (ADRs) of ta-
pentadol. Although drug withdrawal syndrome is a known
ADR of tapentadol, withdrawal occurring at the switch
from the previous WHO step III opioid should be regarded
as associated with the prior treatment, not with tapentadol
PR. Five serious TEAEs were reported in two patients and
included abdominal pain, chest pain, renal pain, transient
ischemic attack, and dysphagia. Six patients in the safety
population (n = 63) had TEAEs that led to premature
study discontinuation. The only TEAEs leading to dis-
continuation reported for[1 patient were nausea (3.2 % [2/
63]) and hyperhidrosis (3.2 % [2/63]).
No clinically relevant changes were observed in vital
signs, laboratory values, or physical examination
parameters.
3.5 Substudies A and B
In Substudy A (n = 21), 81.0 % (17/21) of patients
reduced their doses of WHO step I analgesics and 19.0 %
(4/21) reduced their doses of co-analgesics from Week 9 to
Week 11. The WHO step I analgesics that were tapered
included paracetamol (acetaminophen), metamizole (dipy-
rone), diclofenac, ketoprofen, and meloxicam; the co-
analgesics that were tapered included pregabalin, gaba-
pentin, and flupirtine. Overall, 94.1 % (16/17) of patients
in Substudy A tapered and completely stopped taking their
doses of WHO step I analgesics, and 75 % (3/4) of patients
tapered and completely stopped taking their co-analgesics.
In Substudy A, responder rate 1 was 95.2 % (20/21) and
responder rate 2 was 90.5 % (19/21) at Week 6 (LOCF);
mean (SD) pain intensity score (11-point NRS-3) decreased
significantly from baseline (4.5 [0.60]) to Week 6 (mean
[SD] change from baseline, -2.2 [1.63]; P \ 0.0001),
Week 8 (-3.0 [1.60]; P \ 0.0001), and Week 12 (-3.2
[1.57]; P \ 0.0001).
All patients who participated in Substudy B (n = 21)
tapered and completely stopped taking their side-effect













































































Week –1 (on WHO step III treatment; n = 63)
Week 12 (on tapentadol prolonged release treatment; n = 54)
Fig. 7 Prevalence of AEs
(C2 %) associated with
previous treatment at Week -1
and related to tapentadol
treatment at Week 12 (safety
population; n = 63)a. AE
adverse event, WHO World
Health Organization
aThe prevalence of these AEs
were summarized during Week
-1 (the week prior to titration
when patients were still on
WHO step III treatment) and
during Week 12 (the final week
of tapentadol prolonged release
treatment)
bNausea, constipation, dry
mouth, fatigue, and dizziness
were reported as the main
reasons for switching to
tapentadol prolonged release
Table 5 Equianalgesic ratios of tapentadol to World Health Organi-
zation step III opioids (main analysis population)a





Oxycodone (oral) 7 4.3:1 4.6:1
WHO World Health Organization, PR prolonged release, IR imme-
diate release
a Equianalgesic ratios of tapentadol to other prior WHO step III
opioids are not presented because of low patient numbers
b Ratios based on data available for 48 patients who received prior
treatment with buprenorphine and 4 patients who received prior
treatment with oxycodone
c Ratios based on data available for 48 patients who received prior
treatment with buprenorphine and 6 patients who received prior
treatment with oxycodone
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4 Discussion
The selected population of this trial was defined as patients
with severe pain related to knee osteoarthritis who had
responded to previous strong (WHO step III) opioid ther-
apy. A pain intensity score (NRS-3) B5 at baseline was
believed to be adequate to define the respective population
because pain intensity was measured under treatment with
strong opioids (and not after a washout period, as is typical
in phase 3 trials). The need for strong opioid therapy was
assumed as a prerequisite for patients who entered the trial.
The objective of the trial was generally not to obtain better
analgesia in this strong-opioid responder population but to
reach comparable effectiveness outcomes with better tol-
erability after rotation. Results were more positive than
anticipated and showed that treatment with tapentadol PR
(50–250 mg twice daily) resulted, on average, in better
pain relief compared with previous WHO step III opioids
in patients with severe, chronic osteoarthritis knee pain
who had responded to WHO step III opioids but reported a
lack of tolerability.
The percentage of patients reporting the same or less
pain compared with the 1-week observation period on their
previous WHO step III analgesic regimen increased from
the interim visit to Week 4, then remained above 90 % for
the remainder of the study. A similar high percentage of
patients (*90 %) reported the same or less pain compared
with Week -1 and an improvement in their satisfaction
with treatment from Week 4 of tapentadol treatment
throughout the remainder of the study. Although the
patients included in this study had responded to their pre-
vious WHO step III opioid regimen, tapentadol PR treat-
ment resulted in significant improvements in mean pain
intensity score compared with Week -1 at all weeks of
major comparison (Weeks 6, 8, and 12). This unexpected
and pronounced improvement in pain intensity upon
switching from prior opioid therapy for strong-opioid
responders was the main underlying reason for the trial
being positive and reaching the primary endpoint despite
the small sample size. The improvements observed in mean
pain intensity score with tapentadol PR treatment were
accompanied by improvements in health status, quality-of-
life, function, and anxiety and depression.
Overall, tapentadol treatment was effective for the
management of severe osteoarthritis pain. Osteoarthritis
pain has historically been described as nociceptive pain and
is frequently used as a model of nociceptive pain in regu-
latory guidelines [7–9, 19, 40]. However, the diversity of
underlying conditions associated with osteoarthritis, the
effects of sensitization and chronicity, and the frequently
missing correlation between cartilage damage (radiological
findings) and pain need to be considered when determining
pain origins [7]. The efficacy of compounds such as dul-
oxetine, which act on the descending inhibitory pathway,
show the relevance of targeting this modulatory pain
pathway in osteoarthritis [41]. Further, the efficacy of
opioids may result from effects on the ascending pathway,
targeting particularly pain associated with continuing
mechanical damage and tissue degradation [15, 42]. Thus,
combining an opioid and a noradrenergic mechanism of
action may be of particular relevance in the management of
severe osteoarthritis pain.
Tapentadol PR was associated with improvements in
tolerability relative to previous WHO step III treatments
(based on the prevalence of AEs reported as associated
with previous treatment during Week -1 and related to
tapentadol treatment at Week 12). In particular, the AEs of
nausea, constipation, dry mouth, and fatigue, which were
among the most commonly reported AEs associated with
previous treatment during Week -1, were reduced by
50–75 % by Week 12 of tapentadol PR treatment. In
combination with the results indicating maintenance or
0 5 10 15 20 25
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Skin and subcutaneous tissue disorders
Fatigue
Drug withdrawal syndrome



















SOC TEAEFig. 8 Incidence of TEAEs
reported by C5 % of patients
(safety population; n = 63)
(percentages based on the
number of individual TEAEs
and TEAEs in each SOC). The
horizontal dotted lines separate
the TEAEs included in each
SOC. TEAE treatment-emergent
adverse event, SOC system
organ class
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improvement of pain relief for patients rotating from WHO
step III opioids to tapentadol PR, the low incidence of drug
withdrawal symptoms and low rate of treatment discon-
tinuation indicate that rotation directly from WHO step III
opioids to tapentadol PR went smoothly. A high percentage
of patients achieved appropriate pain relief with just the
starting dose of tapentadol PR (most frequently 50 mg
twice daily). Overall, the tolerability profile of tapentadol
PR in this study is consistent with that observed in previous
placebo-controlled trials [24, 27]. Improvements in toler-
ability versus earlier trials can be explained by a lower dose
range (achieved by allowing for the optional use of con-
comitant analgesics [e.g., NSAIDs], as is common in
practice conditions) and opioid pretreatment.
The equianalgesic ratio calculated in the current study
versus oxycodone was in line with observations from
previous phase 3 studies [24, 27]; however, the equianal-
gesic ratios calculated in the current study were limited by
small sample sizes. The most commonly used analgesic
during Week -1 was transdermal buprenorphine, with a
mean release rate of 20 lg/h (corresponds to
MED = 51.5 mg/day). Given the low dose that patients
taking buprenorphine needed to attain sufficient pain relief
during Week -1, many of these patients were able to
achieve adequate pain relief with low doses of tapentadol
PR, resulting in favorable AE and discontinuation profiles
and further improvements in pain intensity.
For practical aspects when rotating to tapentadol, it
might be recommended that patients be treated with doses
no more than 30 % below the calculated equianalgesic
dose of the previous strong opioid or that an equianalgesic
conversion be targeted (in patients judged to be at higher
risk for developing withdrawal symptoms). These strate-
gies might help to avoid the risk of withdrawal, considering
that tapentadol has less of an opioid component to over-
come withdrawal symptoms related to the previous opioid
treatment.
Possible limitations of this study are the high number of
patients taking buprenorphine (which may not be repre-
sentative of opioid consumption patterns in a general
patient population), the open-label study design, and the
lack of a placebo or active control to allow comparison of
results obtained with tapentadol. The design of this effec-
tiveness trial was intended to better approximate clinical
practice than randomized, placebo-controlled trials.
Effectiveness studies evaluate outcomes that reflect the
overall effects of a study drug (e.g., quality of life, patient-
reported outcomes, changes in pain intensity over time),
providing results that may be more broadly applicable to
the general population observed in clinical practice than the
more narrow efficacy outcomes obtained in a randomized,
controlled trial [43]. Further, the use of a placebo control in
this study would have been unethical because this study
was designed to assess direct rotation from prior strong
opioid therapy to study treatment (tapentadol PR) in a
preselected population of patients with severe pain who
had responded to opioid therapy but showed a lack of
tolerability; rotating these patients from their prior opioid
treatment to placebo would have resulted in withdrawal
reactions and unnecessary pain peaks. Overall results were
unexpectedly positive in this strong-opioid responder
population with severe pain and in line with those of pre-
vious randomized, double-blind, placebo- and active-con-
trolled phase 3 studies of tapentadol PR for the
management of moderate-to-severe, chronic pain [24, 25,
27, 28]; significant improvements in pain intensity were
observed with tapentadol PR treatment over the course of
those studies. In addition, results (as described previously)
were consistent regardless of whether an imputation
method (LOCF) was used or not. In this study, direct
rotation from strong opioids to tapentadol was studied for
the first time in a phase 3b clinical trial setting and pro-
vided valuable data for clinical practice.
Although the populations of the tapering substudies
(Substudies A and B) were relatively small (n = 21 for
each substudy), which limited the statistical evaluation of
these data, results support those observed for the overall
population. Pain relief was maintained with tapentadol PR
treatment after tapering of WHO step I analgesics or co-
analgesics, and there was no increase in adverse effects
after tapering of medications used to treat adverse effects
associated with previous WHO step III opioid therapy.
5 Conclusions
In this phase 3b study, patients with severe osteoarthritis
pain who had responded to WHO step III opioids switched
directly from their previous WHO step III therapy to ta-
pentadol PR without disruption of pain relief and often
experienced improvements in tolerability, as well as further
improvements in pain intensity, function, and quality of
life. Equianalgesic ratios were calculated for tapentadol to
transdermal buprenorphine and oral oxycodone and were
in line with observations from previous phase 3 studies
[24, 27].
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